{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:42:43Z","timestamp":1790016163568,"version":"4.0.1"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CFTR modulator therapies have positive clinical outcomes, yet chronic inflammation and bacterial infections persist in people with CF (pwCF). How elexacaftor\u2013tezacaftor\u2013ivacaftor (ETI) fails to improve innate immune signaling responsible for bacterial clearance and inflammation resolution remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We used an unbiased proteomics approach to measure the effect of ETI on inflammatory proteins. Plasma from 20 pediatric pwCF and 20 non-CF (NCF) was collected during routine examination and 3 months after ETI initiation. Protein screening was performed with an inflammation panel (Target 96, Olink\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ). Bioinformatics analysis was used to determine changes in protein expression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were significantly fewer pulmonary exacerbations after ETI initiation, along with sustained improvement in lung function and reduced bacterial colonization. Unpaired analysis of CF pre-ETI and NCF resulted in 34 significantly different proteins. Of these, CCL20, MMP-10, EN-RAGE, and AXIN1 had a log\n                      <jats:sub>2<\/jats:sub>\n                      fold change of 1.2 or more. There was a modest shift in overall CF protein profiles post-ETI toward the NCF cluster. Unpaired analysis of protein differential expression between NCF and CF post-ETI identified a total of 24 proteins significantly impacted by ETI therapy (\n                      <jats:italic>p<\/jats:italic>\n                      -value \u2264 0.05), with only CCL20 having a log\n                      <jats:sub>2<\/jats:sub>\n                      fold change higher than 1.2. Paired analysis (CF pre- and CF post-ETI) of differential protein expression demonstrated significant expression changes of MMP-10, EN-RAGE, and IL-17A. Pathway analysis identified significantly impacted pathways such as the NF-\u03baB pathway.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study showed that ETI in a pediatric cohort had a modest effect on several inflammatory proteins with potential as biomarkers. Pathways significantly impacted by ETI can be further studied for future therapies to combat persistent inflammation and dysregulated immunity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1486784","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T01:44:19Z","timestamp":1738028659000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Proteomics profiling of inflammatory responses to elexacaftor\/tezacaftor\/ivacaftor in cystic fibrosis"],"prefix":"10.3389","volume":"16","author":[{"given":"Hazel","family":"Ozuna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Bojja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Partida-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luanne","family":"Hall-Stoodley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Amer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Rodney D.","family":"Britt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bum-Yong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Miralda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha L.","family":"Durfey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin T.","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/gut.48.2.198","article-title":"Age and disease related changes in intestinal bacterial populations assessed by cell culture, 16S rRNA abundance, and community cellular fatty acid profiles","volume":"48","author":"Hopkins","year":"2001","journal-title":"Gut"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.5HI1117-454RR","article-title":"Frontline science: pathological conditioning of human neutrophils recruited to the airway milieu in cystic fibrosis","volume":"104","author":"Forrest","year":"2018","journal-title":"J Leukoc Biol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201605-1027OC","article-title":"Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis","volume":"195","author":"Chalmers","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12967-017-1193-9","article-title":"Cystic fibrosis: current therapeutic targets and future approaches","volume":"15","author":"Rafeeq","year":"2017","journal-title":"J Transl Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00146807","article-title":"Inhibition of airway proteases in cystic fibrosis lung disease","volume":"32","author":"Griese","year":"2008","journal-title":"Eur Respir J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"6221","DOI":"10.1038\/ncomms7221","article-title":"Pharmacological modulation of the Akt\/microrna-199a-5p\/Cav1 pathway ameliorates cystic fibrosis lung hyper-inflammation","volume":"6","author":"Zhang","year":"2015","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e11044","DOI":"10.1371\/journal.pone.0011044","article-title":"Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients","volume":"5","author":"Cox","year":"2010","journal-title":"PloS One"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1120577109","article-title":"Decade-long bacterial community dynamics in cystic fibrosis airways","volume":"109","author":"Zhao","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.1.9808096","article-title":"Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients","volume":"160","author":"Muhlebach","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10070766","article-title":"Systems biology and bile acid signalling in microbiome-host interactions in the cystic fibrosis lung","volume":"10","author":"Woods","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.1144","article-title":"Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis","volume":"32","author":"Rosenfeld","year":"2001","journal-title":"Pediatr Pulmonol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/21.089","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor on hospitalizations and intravenous antibiotic use","volume":"26","author":"Walter","year":"2022","journal-title":"Perm J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-216265","article-title":"Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomized trials","volume":"77","author":"Keogh","year":"2022","journal-title":"Thorax"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.resmer.2021.100829","article-title":"Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease","volume":"80","author":"Martin","year":"2021","journal-title":"Respir Med Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22700","article-title":"Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosis","volume":"11","author":"DiMango","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"key":"B19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.852551","article-title":"Short-term effects of elexacaftor\/tezacaftor\/ivacaftor combination on glucose tolerance in young people with cystic fibrosis-an observational pilot study","volume":"10","author":"Korten","year":"2022","journal-title":"Front Pediatr"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2022","journal-title":"J Cyst Fibros"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11144149","article-title":"Impact of CFTR modulators on beta-cell function in children and young adults with cystic fibrosis","volume":"11","author":"Piona","year":"2022","journal-title":"J Clin Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.08.021","article-title":"Whole-blood transcriptomic responses to lumacaftor\/ivacaftor therapy in cystic fibrosis","volume":"19","author":"Kopp","year":"2020","journal-title":"J Cyst Fibros"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800076","article-title":"Dysregulated calcium homeostasis in cystic fibrosis neutrophils leads to deficient antimicrobial responses","volume":"201","author":"Robledo-Avila","year":"2018","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"17066","DOI":"10.1038\/s41598-018-35151-7","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1502609","article-title":"Human cystic fibrosis macrophages have defective calcium-dependent protein kinase C activation of the NADPH oxidase, an effect augmented by Burkholderia cenocepacia","volume":"198","author":"Assani","year":"2017","journal-title":"J Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02861-2021","article-title":"Cystic fibrosis macrophage function and clinical outcomes after elexacaftor\/tezacaftor\/ivacaftor","author":"Zhang","year":"2022","journal-title":"Eur Respir J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00725-2022","article-title":"Elexacaftor\/tezacaftor\/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis","volume":"61","author":"Cavinato","year":"2023","journal-title":"Eur Respir J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1180282","article-title":"Multimodal analysis of granulocytes, monocytes, and platelets in patients with cystic fibrosis before and after elexacaftor-tezacaftor-ivacaftor treatment","volume":"14","author":"Schmidt","year":"2023","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"11995","DOI":"10.1038\/s41598-023-38300-9","article-title":"Comparative effects of CFTR modulators on phagocytic, metabolic and inflammatory profiles of CF and non-CF macrophages","volume":"13","author":"Aridgides","year":"2023","journal-title":"Sci Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PloS One"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1093\/nar\/gkr424","article-title":"Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood","volume":"39","author":"Lundberg","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1038\/s41467-023-38785-y","article-title":"ExpressAnalyst: a unified platform for RNA-sequencing analysis in non-model species","volume":"14","author":"Liu","year":"2023","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e0294236","DOI":"10.1371\/journal.pone.0294236","article-title":"SRPlot: a free online platform for data visualization and graphing","volume":"18","author":"Tang","year":"2023","journal-title":"PloS One"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2439","article-title":"A small-molecule enhancer of signal transducer and activator of transcription 1 transcriptional activity accentuates the antiproliferative effects of IFN-gamma in human cancer cells","volume":"67","author":"Lynch","year":"2007","journal-title":"Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-129718","article-title":"Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3","volume":"112","author":"Nelson","year":"2008","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2009.02.009","article-title":"Regulation of hepatic sulfotransferase (SULT) 1E1 expression and effects on estrogenic activity in cystic fibrosis (CF)","volume":"114","author":"Falany","year":"2009","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.71310","article-title":"Beta-catenin-NF-kappaB-CFTR interactions in cholangiocytes regulate inflammation and fibrosis during ductular reaction","volume":"10","author":"Hu","year":"2021","journal-title":"eLife"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.756131","article-title":"Inhibition of SIRT2 alleviates fibroblasts activation and pulmonary fibrosis via SMAD2\/3 pathway","volume":"12","author":"Gong","year":"2021","journal-title":"Front Pharmacol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.09.008","article-title":"Higher interleukin-7 serum concentrations in patients with cystic fibrosis correlate with impaired lung function","volume":"18","author":"Seyfarth","year":"2019","journal-title":"J Cyst Fibros"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2004.00683.x","article-title":"Increased soluble CD40 ligand levels in cystic fibrosis","volume":"2","author":"Falco","year":"2004","journal-title":"J Thromb Haemost"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e0168819","DOI":"10.1371\/journal.pone.0168819","article-title":"A high level of soluble CD40L is associated with P. aeruginosa infection in patients with cystic fibrosis","volume":"11","author":"Bustamante","year":"2016","journal-title":"PloS One"},{"key":"B44","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12890-022-01977-1","article-title":"The effect of TGF-beta(1) polymorphisms on pulmonary disease progression in patients with cystic fibrosis","volume":"22","author":"Trojan","year":"2022","journal-title":"BMC Pulm Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2018.1406922","article-title":"TGFbeta as a therapeutic target in cystic fibrosis","volume":"22","author":"Kramer","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"B46","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1165\/rcmb.2007-0464OC","article-title":"Oxidative stress causes IL8 promoter hyperacetylation in cystic fibrosis airway cell models","volume":"40","author":"Bartling","year":"2009","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00088-2023","article-title":"Increased expression of CXCL6 in secretory cells drives fibroblast collagen synthesis and is associated with increased mortality in idiopathic pulmonary fibrosis","volume":"63","author":"Bahudhanapati","year":"2024","journal-title":"Eur Respir J"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-021-04168-y","article-title":"A new era for people with cystic fibrosis","volume":"180","author":"Bierlaagh","year":"2021","journal-title":"Eur J Pediatr"},{"key":"B49","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12931-023-02630-z","article-title":"Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after elexacaftor-tezacaftor-ivacaftor therapy","volume":"24","author":"Martin","year":"2023","journal-title":"Respir Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02861-2021","article-title":"Cystic fibrosis macrophage function and clinical outcomes after elexacaftor\/tezacaftor\/ivacaftor","volume":"61","author":"Zhang","year":"2023","journal-title":"Eur Respir J"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26261","article-title":"Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis","volume":"58","author":"Sheikh","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-11-177","article-title":"Elevated expression of both mRNA and protein levels of IL-17A in sputum of stable cystic fibrosis patients","volume":"11","author":"Decraene","year":"2010","journal-title":"Respir Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.1.404","article-title":"Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis","volume":"175","author":"McAllister","year":"2005","journal-title":"J Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00716-2019","article-title":"IL-17A from innate and adaptive lymphocytes contributes to inflammation and damage in cystic fibrosis lung disease","volume":"57","author":"Hagner","year":"2021","journal-title":"Eur Respir J"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00284-16","article-title":"Interleukin-17 pathophysiology and therapeutic intervention in cystic fibrosis lung infection and inflammation","volume":"84","author":"Hsu","year":"2016","journal-title":"Infect Immun"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00247-2021","article-title":"Cross-talk of inflammatory mediators and airway epithelium reveals the cystic fibrosis transmembrane conductance regulator as a major target","volume":"7","author":"Simoes","year":"2021","journal-title":"ERJ Open Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"899","DOI":"10.4049\/jimmunol.1600502","article-title":"Stromelysin-2 (MMP10) moderates inflammation by controlling macrophage activation","volume":"197","author":"McMahan","year":"2016","journal-title":"J Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01908","article-title":"S100 proteins as an important regulator of macrophage inflammation","volume":"8","author":"Xia","year":"2017","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1183\/16000617.0293-2020","article-title":"Cystic fibrosis-related diabetes and lung disease: an update","volume":"30","author":"Prentice","year":"2021","journal-title":"Eur Respir Rev"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.7.613","article-title":"Expression of S100A12 (EN-RAGE) in cystic fibrosis","volume":"58","author":"Foell","year":"2003","journal-title":"Thorax"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/srep08931","article-title":"The role of receptor for advanced glycation end products in airway inflammation in CF and CF-related diabetes","volume":"5","author":"Mulrennan","year":"2015","journal-title":"Sci Rep"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2015.12.011","article-title":"Advanced glycation end products are elevated in cystic fibrosis-related diabetes and correlate with worse lung function","volume":"15","author":"Hunt","year":"2016","journal-title":"J Cyst Fibros"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nature15729","article-title":"\u2206F508 CFTR interactome remodelling promotes rescue of cystic fibrosis","volume":"528","author":"Pankow","year":"2015","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11747","article-title":"Defective CFTR-beta-catenin interaction promotes NF-kappaB nuclear translocation and intestinal inflammation in cystic fibrosis","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2017.11.013","article-title":"CFTR modulates Wnt\/beta-catenin signaling and stem cell proliferation in murine intestine","volume":"5","author":"Strubberg","year":"2018","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2002-0272OC","article-title":"CCL20 is an inducible product of human airway epithelia with innate immune properties","volume":"29","author":"Starner","year":"2003","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00178508","article-title":"Alveolar macrophages and CC chemokines are increased in children with cystic fibrosis","volume":"34","author":"Brennan","year":"2009","journal-title":"Eur Respir J"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.619442","article-title":"CFTR correctors and antioxidants partially normalize lipid imbalance but not abnormal basal inflammatory cytokine profile in CF bronchial epithelial cells","volume":"12","author":"Veltman","year":"2021","journal-title":"Front Physiol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1172\/jci.insight.157865","article-title":"Tissue-localized immune responses in people with cystic fibrosis and respiratory nontuberculous mycobacteria infection","volume":"7","author":"Hayes","year":"2022","journal-title":"JCI Insight"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.10.019","article-title":"Influence of highly effective modulator therapy on the sputum proteome in cystic fibrosis","volume":"23","author":"Maher","year":"2024","journal-title":"J Cyst Fibros"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2020.06.017","article-title":"Evaluation of airway and circulating inflammatory biomarkers for cystic fibrosis drug development","volume":"20","author":"Jain","year":"2021","journal-title":"J Cyst Fibros"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1486784\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T01:44:23Z","timestamp":1738028663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1486784\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":71,"alternative-id":["10.3389\/fimmu.2025.1486784"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1486784","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"article-number":"1486784"}}